Dideoxy Research Articles

The novel HLA-B*40:01:78 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-B*40:01:78 differs from HLA-B*40:01:02:01 by one nucleotide in exon 3.

The novel HLA-C*01:239 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-C*01:239 differs from HLA-C*01:02:01:01 by one nucleotide in exon 4.

The novel HLA-DRB1*14:07:03 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-DRB1*14:07:03 differs from HLA-DRB1*14:07:01 by one nucleotide in exon 2.

The novel HLA-A*02:1068Q allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-A*02:1068Q differs from HLA-A*02:03:01:01 by one nucleotide in exon 1.

The novel HLA-B*55:131 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-B*55:131 differs from HLA-B*55:02:01:01 by one nucleotide in exon 4.

The novel HLA-B*15:644 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-B*15:644 differs from HLA-B*15:17:01:02 by one nucleotide in exon 4.

The novel HLA-C*01:02:89 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-C*01:02:89 differs from HLA-C*01:02:01:01 by one nucleotide in exon 2.

The novel HLA-DQB1*04:93 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-DQB1*04:93 differs from HLA-DQB1*04:01:01:01 by one nucleotide in exon 2.

The novel HLA-B*15:638 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-B*15:638 differs from HLA-B*15:01:01:01 by one nucleotide in exon 2.

The novel HLA-DPB1*1352:01 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-DPB1*1352:01 differs from HLA-DPB1*02:01:02:01 by one nucleotide in exon 4.

The novel HLA-C*03:04:74 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-C*03:04:74 differs from HLA-C*03:04:01:01 by one nucleotide in exon 6.

The novel HLA-B*35:563 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-B*35:563 differs from HLA-B*35:03:01:01 by one nucleotide in exon 4.

The novel HLA-DRB1*14:246 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-DRB1*14:246 differs from HLA-DRB1*14:18 by one nucleotide in exon 2.

The novel HLA-B*52:110N allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-B*52:110N differs from HLA-B*52:01:01:01 by one nucleotide in exon 3.

The novel HLA-B*55:130 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-B*55:130 differs from HLA-B*55:35 by two nucleotides in exon 2.

The novel HLA-B*35:501 allele, identified by sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-B*35:501 differs from HLA-B*35:02:01:01 by three nucleotides in exon 2.

The novel HLA-C*06:02:102 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-C*06:02:102 differs from HLA-C*06:02:01:01 by one nucleotide in exon 2.

The novel HLA-C*03:04:99 allele, identified by sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-C*03:04:99 differs from HLA-C*03:04:01:01 by one nucleotide in exon 5.

Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non-valvular atrial fibrillation.

Hemorrhage events occur most frequently in anticoagulant therapy for non-valvular atrial fibrillation (NVAF). Rivaroxaban is used widely for routine anticoagulation care. Genetic polymorphisms are thought to contribute to the wide intraindividual variability seen in rivaroxaban metabolism and the anticoagulant response. The aim of this study was to evaluate the effect of drug transport related single-nucleotide polymorphisms (SNPs) on rivaroxaban metabolism and on the risk of a hemorrhage event. A total of 216 Chinese patients with NVAF were enrolled in the study. Rivaroxaban was used for anticoagulation therapy. Rivaroxaban plasma concentrations were detected using a validated ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method. Seven SNPs in four genes were genotyped using the Sanger dideoxy DNA sequencing method. Associations between genotype variants, the incidence of hemorrhage events, and the time of bleeding were analyzed. ABCB1 2677G (rs2032582) variation was highly associated with the dose-adjusted rivaroxaban peak concentration in plasma (Cmax /D) (p=0.025, FDR=0.042). The ABCB1 G allele carriers had a higher rivaroxaban Cmax /D than non-carriers. Logistic regression showed that rivaroxaban Cmax /D and ABCB1 genotype variants were associated with a higher incidence of hemorrhage events. No statistically significant difference was found between ABCB1 genotypes and the time of bleeding after anticoagulant therapy in 30days. These results indicated that ABCB1 2677G (rs2032582) genetic variant affects the rivaroxaban Cmax /Dose and the incidence of hemorrhage events significantly.

Characterization and phylogenetic analyses of the complete mitochondrial genome of Sillaginopsis panijus (Perciformes: Sillaginidae)

The complete mitochondrial genome of Sillaginopsis panijus has been determined for the first time using Sanger Dideoxy DNA sequencing. The mitogenome is a circular molecule of 16,529 bp in length. It contains 37 mitochondrial genes (13 protein-coding genes, two ribosomal RNA, and 22 transfer RNA) and a control region as other bony fishes. In the phylogenetic analysis using 12H-strand protein-coding genes, monotypic S. panijus is situated separately from the genus Sillago. The present phylogeny supports its taxonomic position according to morphology and will be helpful for evolutionary analysis.